Drug Profile

Interferon-beta - Human Genome Sciences

Alternative Names: Albuferon-β

Latest Information Update: 23 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Human Genome Sciences
Class Antineoplastics; Antivirals; Interferons; Skin disorder therapies
Mechanism of Action Interferon beta stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Cancer; Multiple sclerosis

Most Recent Events

25 Oct 2005 No development reported - Preclinical for Cancer in USA (unspecified route)
25 Oct 2005 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
04 Sep 2002 Data from a preclinical study have been added to the pharmacokinetics section

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com